Skip to main content

Table 4 Administration characteristics for IGSC 20 % by age group

From: Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Parametersa Age group All patients (n = 74)
2 to <5 years (n = 1) 5 to <12 years (n = 14) 12 to <16 years (n = 8) 16 to <65 years (n = 45) 65 years and older (n = 9)
Duration of infusions (h)
 Infusions (n) 50 718 346 2614 434 4162
 Median 0.95 0.73 1.18 0.97 0.91 0.95
 Min; max (0.5; 1.4) (0.3; 3.45) (0.3; 3.5) (0.2; 4.2) (0.5; 6.4) (0.2; 6.4)
Number of sites per infusion
 Infusions (n) 52 753 360 2700 461 4326
 Median 1 2.0 2.0 2.0 2.0 2.0
 Min; max (1; 1) (1; 3) (1; 3) (1; 4) (1; 2) (1; 4)
Maximum infusion rate per site (ml/h/ site)
 Infusions (n) 52 749 360 2692 461 4314
 Median 15.0 30.0 50.0 60.0 60.0 60.0
 Min; max 13.5; 20.0 4.4; 80.0 20.0;120.0 10.0; 180.0 5.0; 60.0 4.4; 180.0
Infusion volume per site (ml/site)
 Infusions (n) 52 749 360 2692 461 4314
 Median 14.5 19.5 42.7 45.3 39.0 39.5
 Min; max 13.5; 15.5 6.4; 43.0 19.2; 67.5 18.1; 76.0 31.8; 56.5 6.4; 76.0
  1. aOnly infusions with complete infusion parameters have been considered for each analyses